German Study Group News Today

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

Results from the ADAPTcycle trial found that endocrine therapy plus ovarian suppression can generate high response rates in patients with HR-positive, early breast cancer, regardless of age.

EXAS earnings call for the period ending June 30, 2023.

Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapy Trial reinforces Agendia's

ADAPT Triad minimal residual disease analysis study intended to evaluate the association between circulating tumor DNA (ctDNA) positivity and recurrence intervals MADISON, Wis., Aug. 3

The ADAPT Triad analysis will use data from three ongoing studies to validate the test's ability to inform treatment strategy and monitor recurrence.

/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered a collaboration agreement with...

This oncologic clinical trial evaluates the efficacy and safety of the CDK 4/6 Inhibitor Abemaciclib in combination with endocrine therapy in high-risk early breast cancer patients Cologne, Germany, 07.01.2021 – CANKADO, the leading digital health application developers in Germany, assists the recently started clinical trial, ADAPTlate, organized by West German Study Group (WSG) to collect the Patient Reported Outcomes (PROs) by the CANKADO ePRO tool. The clinical trial already enrolled the...

Following is a transcript of their remarks: Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this years San Antonio Breast Cancer meeting. Im Hope Rugo, professor of medicine at the University of California San Franciscos Comprehensive Cancer Center, and Im joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from...

The tool developed on the basis of the ADAPT study data will be presented today at SABCS 2020 Cologne, Germany, 11.12.2020 – The EnReP (Endocrine Response Predictor) assessment tool will be presented today at the San Antonio Breast Cancer Symposium SABCS 2020. EnReP is a tool developed in Germany that can be used to predict the probability of response to endocrine therapy in early-stage breast cancer patients. Endocrine therapy is the standard therapy for hormone receptor-positive (HR+) / HER...